Absci Corporation · NASDAQ:ABSI
Absci — Investor Presentation (November 2026)
61 slides from Absci's investor presentation, Nov 12, 2026
Slide 1: Corporate Presentation November 2026
Corporate Presentation November 2026 GENERATIVE AI DRUG CREATION CONFIDENTIAL AND PROPRIETARY | COPYRIGHT © 2026 ABSCI CORPORATION | ALL RIGHTS RESERVED
Slide 2: Disclaimers
Disclaimers F O R W A R D - L O O K I N G S T A T E M E N T S Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to
Slide 3: Absci Intro: AI Native Platform, Differentiated Pipeline
AI NATIVE PLATFORM1. DIFFERENTIATED PIPELINE2. From Code to Clinic CONFIDENTIAL AND PROPRIETARY | COPYRIGHT © 2026 ABSCI CORPORATION | ALL RIGHTS RESERVED 3 A B S C I | I N T R O o Interdisciplinary Team with 10+ approved drugs and AI expertise o Integrated Lab-in-the-Loop leveraging 77k ft² automat
Slide 4: Industrializing Drug Discovery
Industrializing Drug Discovery INCREASING ‘SHOTS-ON GOAL’ WITH FASTER AND CAPITAL EFFICIENT DISCOVERY $10-15mil (Absci) $50-100mil (Large Pharma) 24 Months (Absci) 5-6 years (Large Pharma) C A P IT A L IN V E S T M E N T D IS C O V E R Y T IM E L IN E DELIVERING 3 CLINICAL- STAGE PROGRAMS TO DATE 1
Slide 5: Next-Gen Pipeline
*or equivalent ex-US filing N E X T - G E N P I P E L I N E COPYRIGHT © 2026 ABSCI CORPORATION | ALL RIGHTS RESERVED 5 P I P E L I N E T H E R A P E U T I C A R E A T A R G E T I D L E A D I D C A N D I D A T E I D I N D - E N A B L I N G P H A S E 1 P H A S E 2 A B S - 2 0 1 Pattern Hair Loss (PRLR
Slide 6: ABS-201 potential to unlock new category of hair re-growth therapy
ABS-201 has the potential to unlock a wholly new category of therapy in hair “re-growth” Significant clinical and commercial unmet need in Pattern Hair Loss1. Strong scientific rationale, with validated target, de-risked Mode of Action, and pharmacology2. 3. COPYRIGHT© 2026 ABSCI CORPORATION | ALL R
Slide 7: Underserved patient population in Pattern Hair Loss
COPYRIGHT © 2026 ABSCI CORPORATION | ALL RIGHTS RESERVED 7 A B S - 2 0 1 P H L Underserved patient population looking for therapeutic innovation ~80 million Americans live with Pattern Hair Loss (PHL) FEMALE PHL ~30M women in the U.S. Only 1 FDA approved drug therapy for women ~50M men in the U.S. O
Slide 8: PRLR inhibition is an innovative alternative for Pattern Hair Loss
8 A B S - 2 0 1 | P H L PRLR inhibition for Pattern Hair Loss is an innovative alternative to current treatment options P R O P O S E D D I R E C T I M P A C T O F A B S - 2 0 1 O N H A I R C Y C L E S T A G E S Telogen Resting Phase Hair falls out Catagen ↑↑ Apoptosis & Regression 2-4 weeks Anagen
Slide 9: Prolactin impacts on organ-cultured human hair follicles
COPYRIGHT © 2026 ABSCI CORPORATION | ALL RIGHTS RESERVED 9 A B S - 2 0 1 P H L Prolactin impacts on organ-cultured human hair follicles Prolactin prematurely induces a catagen-like stage in organ-cultured human hair follicles1 characterized by: Vehicle 400 ng/ml prolactin Catagen IIIAnagen VI HS M D
Slide 10: PRLR inhibition anticipated safe and well tolerated per human genetics
COPYRIGHT © 2026 ABSCI CORPORATION | ALL RIGHTS RESERVED 10 A B S - 2 0 1 P H L PRLR inhibition anticipated to be safe & well tolerated as supported by human genetics I. II. III. NV = Nonvariant ND = Not determined I. II. III. I. II. III. IV. Kobayashi, 2018 NEJM Moriwaki, 2021 JCEM Newey & Phil , 2
Slide 11: Terminal hair count in primate model of PHL
11 A B S 2 0 1 | P H L Terminal hair count ”Thick Hairs” in prior bald areas o Hair regrowth observed for both male and female animals (>100 hairs/cm2 increase in bald area at week 28 of treatment*) # T hi ck H ai rs Time (w) 200 100 0 250 150 50 300 4 8 12 16 20 24 A S S E S S M E N T A R E A = R 1
Slide 12: ABS-201 superior to 5% topical minoxidil in regrowth model
COPYRIGHT © 2026 ABSCI CORPORATION | ALL RIGHTS RESERVED 12 A B S - 2 0 1 P H L ABS-201 shows superior efficacy vs 5% topical minoxidil in 21d hair regrowth model Administration: mAbs i.p. biweekly; Minoxidil topical daily ABS-201 vs minoxidil/untreated/isotype **p<0.05; ***p<0.0001 - 2way ANOVA Hai
Slide 13: Men without PHL carry genetically lower PRLR levels
COPYRIGHT © 2026 ABSCI CORPORATION | ALL RIGHTS RESERVED 13 A B S - 2 0 1 | P H L Men without PHL carry genetically lower PRLR levels; severity of PHL scales with PRLR expression Notes: • SNP rs6451196, 1.35 is per standard deviation; between the most extreme genotypes, G/G and A/A, it is 1.10. • Ea
Slide 14: cis-MR and colocalization support PRLR causal role in PHL
COPYRIGHT © 2026 ABSCI CORPORATION | ALL RIGHTS RESERVED 14 cis-MR + colocalization supports a causal relationship for PRLR in Pattern Hair Loss A B S - 2 0 1 | P H L o More PRLR, more proportional balding. o The neighboring genes show no association with PHL o The PRLR expression and hair loss sign
Slide 15: ABS-201 ex vivo study supports MOA in human scalp follicles
COPYRIGHT © 2026 ABSCI CORPORATION | ALL RIGHTS RESERVED 15 A B S - 2 0 1 | P H L ABS-201 in human ex vivo culture study supports MOA in human scalp follicles ABS-201 significantly prolongs anagen/inhibits catagen and stimulates hair matrix proliferation Anagen Early Catagen Mid Catagen lgG Ctrl ABS
Slide 16: Additional ABS-201 ex vivo study findings
COPYRIGHT © 2026 ABSCI CORPORATION | ALL RIGHTS RESERVED 16 A B S - 2 0 1 | P H L Additional ABS-201 ex vivo study found: o Prolonging anagen phase and blocking catagen, thereby inhibiting telogen effluvium o Protecting and promoting hair follicle stem cells and and restoring CD34+ progenitor cells
Slide 17: Phase 1/2a trial designed to read out safety, tolerability, PoC in PHL
Phase 1/2a trial designed to provide readouts on safety, tolerability, and PoC in PHL Design Elements: o Double-Blind, Placebo-controlled, FIH o Multi-site study in Australia o Dose range ensures predicted >90% RO Population: o Up to 227 male & female healthy participants o SAD; n= 32 healthy volunt
Slide 18: Half life of >65 days; interim PK data from SAD cohorts
18CONFIDENTIAL AND PROPRIETARY | COPYRIGHT © 2026 ABSCI CORPORATION | ALL RIGHTS RESERVED Half life of >65 days at doses overcoming TMDD PK profile supports targeted dosing interval of 2 or 3 injections over six-month period A B S 2 0 1 | P H L 0 2 4 6 8 10 0.1 1 10 100 1000 Time (Wk) M ea n Se ru m
Slide 19: Modeling of interim PK data supports convenient dosing
CONFIDENTIAL AND PROPRIETARY | COPYRIGHT © 2026 ABSCI CORPORATION | ALL RIGHTS RESERVED 19 A B S - 2 0 1 | P H L o Modeling of interim PK data from HEADLINE Trial supports the potential for 2–3 s.c. injections over six-month period (e.g., 400 mg/injection) to maintain> 90% Receptor Occupancy without
Slide 20: ABS-201 TPP offers new treatment category in PHL
A B S - 2 0 1 | P H L COPYRIGHT © 2026 ABSCI CORPORATION | ALL RIGHTS RESERVED 20 ABS-201 TPP aims to offer a new treatment category in PHL based on efficacy and convenience 0 10 20 30 40 50 60 70 80 Ef fic ac y (t er m in al h ai rs /c m 2) Topical Minoxidil Oral Minoxidil Finasteride PRP Transplan
Slide 21: Consumer research validates market potential of ABS-201
Consumer Research Commissioned by Absci Validates Market Potential of ABS-201 Significant Unmet Need: Driven by psycho-social impacts (loss of confidence, self- esteem) from PHL Strong Commercial Demand: Nearly all men and roughly 90% of women are inclined to ask their doctors about ABS-201 High Val
Slide 22: Patient funnel and estimated TAM for PHL
5-9M Pts Treated/Year Assuming 2-3 Year Durability Patient Funnel >$25B E S T I M A T E D U . S . T A M >$40B P O T E N T I A L G L O B A L T A M Total PHL pts in the US 50M male, 30M female Income ≥$75K (US Census) Pts 17-69 yo Concerned / motivated about hair loss Strong interest in TPP* Strongest
Slide 23: ABS-201 Pattern Hair Loss KTL Advisors
CONFIDENTIAL AND PROPRIETARY | COPYRIGHT © 2026 ABSCI CORPORATION | ALL RIGHTS RESERVED 23 ABS-201 Pattern Hair Loss KTL Advisors Rodney Sinclair, MBBS, MD, FACD Professor of Dermatology, University of Melbourne; Founder & Director, Sinclair Dermatology; Director of Dermatology, Epworth Hospital Lil
Slide 24: ABS-201 in Endometriosis addresses long-standing unmet need
Development of ABS-201 in Endometriosis Addresses Long-standing Unmet Medical Need and Poor standard of care 1. Large, untapped market offers significant upside potential 2. Strong Biological And Clinical Rationale: Including POC for PRLR mechanism in humans 3. COPYRIGHT© 2026 ABSCI CORPORATION | AL
Slide 25: Treatment paradigm for Endometriosis
COPYRIGHT © 2026 ABSCI CORPORATION | ALL RIGHTS RESERVED 25 A B S - 2 0 1 | E N D O M E T R I O S I S Hormonal therapies and surgical intervention make up the treatment paradigm for Endo • Endo is a chronic condition with currently no medical or surgical cure • Roughly, 75% of patients are estimated
Slide 26: PRLR antagonism is a novel MoA in Endometriosis
o Endometriotic lesions produce prolactin under estrogen/progesterone control. o Excess prolactin promotes lesion growth and sensitizes pain-sensing nerves, contributing to chronic pelvic pain. o Prolactin signaling is independent of sex-hormone pathways, offering a differentiated, non-hormonal trea
Slide 27: Prolactin receptor expression in human endometrium
COPYRIGHT © 2026 ABSCI CORPORATION | ALL RIGHTS RESERVED 27 A B S - 2 0 1 E N D O Localization And Temporal Expression Of Prolactin Receptor In Human Endometrium PRL and PRLR increase during secretory phase in healthy tissue, and is overexpressed in endometrium of patients with endometriosis Me = me
Slide 28: Prolactin may regulate pain responses via nociceptor mechanism
COPYRIGHT © 2026 ABSCI CORPORATION | ALL RIGHTS RESERVED 28 A B S - 2 0 1 E N D O Prolactin May Regulate Pain Responses via a Female- Selective Nociceptor-Specific Mechanism PRLR antagonism suppresses postoperative pain in female mice and inhibits endometriosis interna formation The Effects of Prola
Slide 29: PRLR antagonism reduces lesion formation and pain in mouse model
PRLR antagonism reduces lesion formation and pain in endometriosis mouse model 29 A B S - 2 0 1 | E N D O M E T R I O S I S COPYRIGHT© 2026 ABSCI CORPORATION | ALL RIGHTS RESERVED * 1 2 3 4 5 0 * * *D is ea se S co re Control Graft + danazol + faslodex + cetrorelix Prolactin Antagonist Antibody Prol
Slide 30: ABS-201 profile targeting large underserved endometriosis market
COPYRIGHT © 2026 ABSCI CORPORATION | ALL RIGHTS RESERVED 30 >$4.5B at peak sales Potential to generate A B S - 2 0 1 | E N D O M E T R I O S I S ABS-201: a potentially differentiated profile targeting a large underserved market opportunity NOVEL TREATMENT OPTION FOR ~9M PATIENTS IN THE U.S. ALONE WI
Slide 31: Endometriosis Advisory Board
COPYRIGHT © 2026 ABSCI CORPORATION | ALL RIGHTS RESERVED 31 Clinical Strategy guided by an Endometriosis Advisory Board Hugh Taylor, MD C H A I R Anita O’Keefe Young Professor Chair, Ob/Gyn & Reproductive Sciences, Yale School of Medicine Joan-Carles Arce, MD, PhD Chief Scientific Medical Officer &
Slide 32: Phase readouts in the next 24 months
Leading AI x Bio platform driving 2 Phase 2 readouts in the next 24 months COPYRIGHT © 2026 ABSCI CORPORATION | ALL RIGHTS RESERVED 32 C A T A L Y S T S ABS-201 in PHL o Ph1/2a Study initiated Dec 2025 o Positive interim Safety, Tolerability, and PK readout June 2026 o Interim PoC Readout – anticipa
Slide 33: Powered by Absci's Leading AI Platform
CONFIDENTIAL AND PROPRIETARY | COPYRIGHT © 2026 ABSCI CORPORATION | ALL RIGHTS RESERVED 33PYRIGH © 2026 ABSCI CORPORATION | ALL RIGHTS RE ERVED Powered by Absci’s Leading AI Platform
Slide 34: De novo AI models deliver differentiated lead candidates
34COPYRIGHT© 2026 ABSCI CORPORATION | ALL RIGHTS RESERVED A B S C I | A I P L A T F O R M Absci's de novo AI models deliver differentiated lead candidates against challenging targets *May include one week of AI lead optimization • Address challenging targets – Only target structure or sequence requi
Slide 35: We use AI to create novel and differentiated therapeutics
COPYRIGHT © 2026 ABSCI CORPORATION | ALL RIGHTS RESERVED 35 D E N O V O D E S I G N We use AI to create novel & differentiated therapeutics ENABLING FEATURES: MULTI-VALENCY, pH-DEPENDENT BINDING ABILITY TO ADDRESS DIFFICULT TARGET CLASSES, E.G. GPCRS EPITOPE-SPECIFIC DESIGN + EPITOPE INTERFACE OPTIM
Slide 36: Experimentally validated AI technology for de novo antibody design
COPYRIGHT © 2026 ABSCI CORPORATION | ALL RIGHTS RESERVED 36 We create experimentally validated AI technology that enables de novo antibody design A I P L A T F O R M Antibody Design (AbsciDesign) Library Design Wet Lab Validation (1) Generate antibody structures and sequences. (2) Filter designs tow
Slide 37: AI models design and optimize therapeutic antibodies
37COPYRIGHT© 2026 ABSCI CORPORATION | ALL RIGHTS RESERVED A B S C I | A I P L A T F O R M 1. Target structure(s) 2.Epitope(s) 3.Antibody framework(s) 4.CDR lengths CDR = Complementarity Determining Region H = Heavy Chain; L = Light Chain Design 1 HCDR1: GFNIKDTY HCDR2: IYPTNGYT HCDR3: SRWGGDGFYAMDY
Slide 38: Lab-in-the-loop ensures AI-designed antibodies become drug-ready
38COPYRIGHT© 2026 ABSCI CORPORATION | ALL RIGHTS RESERVED A B S C I | A I P L A T F O R M Lab-in-the-loop ensures AI-designed antibodies translate into drug- ready candidates Ideal Drug Candidates Easy to produce Good physico- chemical behavior Stable High Affinity Functional validation • Screening
Slide 39: Introducing Origin-1 for de novo antibody design
39COPYRIGHT© 2026 ABSCI CORPORATION | ALL RIGHTS RESERVED Introducing Origin-1: an AI platform for de novo antibody design against zero-prior epitopes Zero-Prior Epitope Targeting Designed full-length mAbs against epitopes with no known protein binders or structural data in <100 designs per target H
Slide 40: De novo models deliver leads against challenging targets
40COPYRIGHT© 2026 ABSCI CORPORATION | ALL RIGHTS RESERVED A B S C I | A I P L A T F O R M Absci’s de novo AI models deliver differentiated lead candidates against challenging targets DE NOVO ANTIBODY DESIGN AGAINST TRANSMEMBRANE TARGET EPITOPE WITH NO KNOWN BINDER Designed seven high-affinity antibo
Slide 41: High-fidelity datasets enrich for developable candidates
41COPYRIGHT© 2026 ABSCI CORPORATION | ALL RIGHTS RESERVED A B S C I | A I P L A T F O R M We use high-fidelity, customized datasets with our own AI models to enrich for developable candidates Lab-in-the-loop synergy provides strong model performance out to >1018 combinatorial space* Generates divers
Slide 42: AI-design and optimization of multiple properties
42COPYRIGHT© 2026 ABSCI CORPORATION | ALL RIGHTS RESERVED A B S C I | A I P L A T F O R M Success in AI-design and optimization of multiple developability and pharmacological properties CROSS-SPECIES OPTIMIZATION Successful design of antibodies binding to both mouse and human antigens • Hits identif
Slide 43: Track record of industry-leading partnerships
Track record of industry-leading partnerships A I D R U G C R E A T I O N ™ P A R T N E R S H I P S O U R P A R T N E R S H I P F O C U S 25+ PARTNERED PROGRAMS TO DATE • Challenging Targets / Epitopes • Differentiated TPPs • Mono or Multi-specific Formats A B S C I | P A R T N E R S H I P S U P P O
Slide 44: Multilingual team with expertise in AI and drug creation
”Multilingual” team with expertise in AI and drug creation COPYRIGHT © 2026 ABSCI CORPORATION | ALL RIGHTS RESERVED 44 T E A M Sean McClain Founder, CEO & Board Director Zach Jonasson, PhD Chief Financial Officer & Chief Business Officer Shelby Walker, JD Chief Legal Officer L e a d e r s h i p T e
Slide 45: Absci at a Glance
45 100+ E M P L O Y E E S Biologics drug discovery expertise from: “Multi-lingual” AI + Drug Discovery expertise AI team drawing on experience from tech leaders: 77,000 S Q U A R E F E E T o State-of-the-art wet and dry lab in Vancouver WA o Absci AI Research (AAIR) lab in NYC o Innovation Centre in
Slide 46: Generative AI Re(Generative) Biology
Generative AI Re(Generative) Biology A B S C I C O R P O R A T I O N 2 0 2 6 A L L R I G H T S R E S E R V E D
Slide 47: AI Case Study I: de novo design of antibody binding HIV Caldera
47C O P Y R I G H T © 2 0 2 6 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . A I C A S E S T U D Y I de novo design of an antibody that binds the Caldera region of HIV-1 trimer
Slide 48: No antibody universally neutralizing HIV exists today
COPYRIGHT © 2026 ABSCI CORPORATION | ALL RIGHTS RESERVED 48 No natural or synthetic antibody for HIV exists today because immune system cannot derive an antibody that is universally neutralizing against HIV Design challenge: create universally neutralizing HIV antibody by binding unique and conserve
Slide 49: HIV-Caldera: determine inputs and design
COPYRIGHT © 2026 ABSCI CORPORATION | ALL RIGHTS RESERVED 49 D e n o v o d e s i g n HIV-Caldera: Determine inputs and design HIV Env Trimer Challenge : • Highly glycosylated • Extremely high sequence diversity among isolates • High mutation rate at common neutralizing epitopes Model inputs: 1. Antig
Slide 50: Best structures selected from 10,000+ generated
COPYRIGHT © 2026 ABSCI CORPORATION | ALL RIGHTS RESERVED 50 D E N O V O D E S I G N 4 best structures selected from 10,000+ structures generated by de novo model 17b Structure S1 HCDR3 Structure S3 HCDR3 Structure S2 HCDR3 Structure S4 HCDR3 HeavyLight
Slide 51: Molecular dynamics simulation applied to de novo designed antibodies
COPYRIGHT © 2026 ABSCI CORPORATION | ALL RIGHTS RESERVED 51 2024 20252024 2025 2026 Applied molecular dynamics simulation to de novo designed antibodies C A S E S T U D Y # 1
Slide 52: Enriched de novo library binds open Env trimer
COPYRIGHT © 2026 ABSCI CORPORATION | ALL RIGHTS RESERVED 52 H A ta g Antigen Clade A Env trimer Closed Open Enriched de novo library binds open, not closed, Env trimer conformation in YSD Closed Open Clade B Env trimer D E N O V O D E S I G N
Slide 53: SPR data consistent with caldera binding
COPYRIGHT © 2026 ABSCI CORPORATION | ALL RIGHTS RESERVED 53 D E N O V O D E S I G N SPR data demonstrate binding characteristics consistent with binding of caldera
Slide 54: HIV-Caldera: no binding to GP120 monomer
COPYRIGHT © 2026 ABSCI CORPORATION | ALL RIGHTS RESERVED 54 HIV-Caldera: SPR demonstrates no binding of de novo designs to GP120 monomer Hypothesis: If the designed mAbs are binding to the caldera region we should not observe binding to monomeric GP120 since the caldera is only present in the Env tr
Slide 55: HIV-Caldera summary and next steps
COPYRIGHT © 2026 ABSCI CORPORATION | ALL RIGHTS RESERVED 55 HIV-Caldera: demonstrating AI de novo design for challenging target SUMMARY de novo design model created a novel and diverse antibody which binds multiple clades of HIV indicating successful targeting of the caldera epitope Screening cascad
Slide 56: AI Case Study II: AI Optimization for pH Sensitivity
56C O P Y R I G H T © 2 0 2 6 A B S C I C O R P O R A T I O N . A L L R I G H T S R E S E R V E D . AI CASE STUDY I I A I O p t i m i z a t i o n f o r p H s e n s i t i v i t y
Slide 57: AI lead optimization platform for smart biologics
AI lead optimization platform for ‘smart biologics’ COPYRIGHT© 2026 ABSCI CORPORATION | ALL RIGHTS RESERVED 57 C A S E S T U D Y # 2 The Challenge The diversity of antibodies is vast, making it impossible for traditional methods to explore effectively. Absci Solution Our AI can search a space of ~10
Slide 58: pH sensitivity may reduce toxicity or improve efficacy
pH sensitivity may reduce toxicity and/or improve efficacy of therapeutic mAbs COPYRIGHT© 2026 ABSCI CORPORATION | ALL RIGHTS RESERVED 58 C A S E S T U D Y # 2 Tumor specificity improves efficacy and reduces ”on-target off-tumor” toxicities Binding occurs in the acidic pH of the tumor microenvironme
Slide 59: Models identify pH sensitive Fab variants
Models identify pH sensitive Fab variants from the same lead for either indication COPYRIGHT© 2026 ABSCI CORPORATION | ALL RIGHTS RESERVED 59 C A S E S T U D Y # 2 1. Library for model training sampled 60 positions on heavy chain framework and CDRs with up to 7 substitutions biased for ionizable res
Slide 60: Hits reformatted as mAbs show desired binding profiles
COPYRIGHT © 2026 ABSCI CORPORATION | ALL RIGHTS RESERVED 2024 20252024 2025 2026 Hits reformatted as mAbs show desired binding profiles SUMMARY AI optimized leads achieves variants with pH sensitive binding up to 100x differential pH-sensitive leads had no liabilities for stability, aggregation and
Slide 61: Summarized platform case studies
COPYRIGHT © 2026 ABSCI CORPORATION | ALL RIGHTS RESERVED 61 Summarized platform case studies C A S E S T U D I E S de novo Design de novo design model created molecule binds multiple clades of HIV suggesting successful targeting of the caldera epitope Represents second disclosed target success for o